Editorial Comment
Yujin Xu, Weiguo Zhu, Jianc
Abstract
This prospective clinical trial summary provides the background and rationale for evaluating optimal radiation dose for definitive concurrent chemo-radiation for inoperable esophageal carcinoma. We designed the multi-center clinical trial comparing the efficacy of high dose group (60 Gy/30F) with low dose group (50 Gy/25F) concurrent with weekly chemotherapy using 3D-CRT or IMRT technology for esophageal carcinoma. The primary outcome is local/ regional progression-free survival, and secondary outcomes include Overall survival; local control rate; patterns of treatment failure; toxicity; radiation-related advent events.